Shield Therapeutics (STX)

Company name:Shield Therapeutics Plc
EPIC:STXTrading Currency:GBX
Market Sector:AMQ1ISIN:GB00BYV81293
Market Segment:ASQ1Share Type:DE
WWW Address: 1.5P
 Price Price Change [%] Bid Offer Open High Low Volume
 188.00 0.0 [0.00] 187.00 189.00 188.00 188.00 188.00 43,217
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 220.13 117.09 -0.08 -2.00 - - - 201.00 - 28.50

Shield Therapeutics Key Figures

(at previous day's close)
Market Cap.220.13m
Shares In Issue117.09m
Prev. Close188.00
PE Ratio- 
Dividend Yield-%
EPS - basic-2.00p
Dividend PS-p
Dividend Cover- 
Cash Flow PS-0.15p
Return On Equity (ROE)-4.44%
Operating Margin-43.37%
PEG Factor- 
EPS Growth Rate88.24%
Dividends PS Growth Rate-%
Net Debt-6.83m
Gross Gearing6.80%
Quick Assets12.31m
Net Working Capital9.47m
Intangibles / Fixed Assets99.97%
Turnover PS10.15p
Pre-Tax Profit PS-4.40p
Retained Profit PS-1.53p
Cash PS8.35p
Net Cash PS5.83p
Net Tangible Asset Value PS *8.09p
Net Asset Value PS34.53p
Spread2.00 (1.06%) 

Shield Therapeutics Balance Sheet


Share Price Performance

Sample Period HighLow
1 week191.00187.50
4 weeks195.00178.00
12 weeks195.00178.00
1 year201.0028.50

Share Price Chart (5 years)

Shield Therapeutics Historic Returns

Period OpenChange%Open Avg.Avg. Daily Vol [m]Total Vol [m]VWAP
1 week189.50-1.50-0.79187.500.08189.87
4 weeks181.506.503.58178.000.22188.78
12 weeks185.502.501.35178.000.11186.95
26 weeks116.0072.0062.07102.500.15170.24
1 year31.50156.50496.8328.500.17120.87
3 years173.0015.008.6713.000.1479.37
5 years154.5033.5021.6813.000.1282.30

Shield Therapeutics Key Management Ratios

Shield Therapeutics Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio- 
PE Ratio- 
Tobin's Q Ratio 4.98 
Tobin's Q Ratio (excl. intangibles)16.05 
Dividend Yield-%
Market-to-Book Ratio5.44 
Price-to-Pre-Tax Profit PS-42.72 
Price-to-Retained Profit PS-122.70 
Price-to-Cash Flow PS-1,236.67 
Price-to-Sales PS18.53 
Price-to-Net Tangible Asset Value PS23.24 
Price-to-Cash PS22.52 
Net Working Capital PS8.08 
Price Pct to Working Capital PS23.26%
Earnings Yield-%
Average PE- 
Years in average- 
PE to PE average-%

Shield Therapeutics Financial Ratios

(Leverage Ratios)
Debt Ratio-%
Debt-to-Equity Ratio- 
Debt-to-Equity Ratio (excl. Intgbl)- 
Debt-to-Equity Market Value- 
Net Gearing-15.73%
Net Gearing (excl. Intangibles)-54.93%
Gross Gearing6.80%
Gross Gearing (excl. Intangibles)23.75%
Gearing Under 1 Year6.80%
Gearing Under 1 Year (excl. Intgbl)23.75%
(Liquidity Ratios)
Net Working Capital to Total Assets21.82%
Current Ratio4.21 
Quick Ratio (Acid Test)4.17 
Liquidity Ratio3.31 
Cash & Equiv/Current Assets78.74%
(Solvency Ratios)
Enterprise Value210.35m
CFO/Attributable Profit- 
Total Debt/Equity Market Value0.01 
Total Debt/Sales0.25 
Total Debt/Pre-Tax Profit-0.57 
Total Debt2.95m
Total Debt/Net Current Assets0.31%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth-48.91%
5 yr Compound Earnings Growth-%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs2 
Beta (60-Mnth)Beta (36-Mnth)

Shield Therapeutics Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)-12.75%
Return On Assets (ROA)-4.06%
Net Profit Margin-15.10%
Assets Turnover0.27 
Return On Equity (ROE)-4.44%
Return On Investment (ROI)-4.40%
Dividend Payout Ratio-%
Plowback Ratio100.00%
Growth from Plowback Ratio-%
Net Income Of Revenues-15.10%
(Asset Utilisation Multiples)
Shareholders Equity Turnover0.29 
Fixed Assets Turnover0.39 
Current Assets Turnover0.87 
Net Working Capital Turnover 
Inventory Turnover101.55 
(Other Operating Ratios)
Total Assets-to-Sales3.72 
Debt Collection Period63.02Days

Shield Therapeutics Dividends

Sorry No Data Available

Shield Therapeutics Fundamentals

 31 Dec 2015 (GBP)31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)
pre tax profit-24.49--15.60--20.99--5.15-43.37%m
attributable profit-23.88--15.02--19.59--1.79-15.10%m
retained profit-23.88--15.02--19.59--1.79-15.10%m
eps - basic (p)57.00 -15.00 -17.00 -2.00 
eps - diluted (p)57.00 -15.00 -17.00 -2.00 
dividends per share- - - - 

Shield Therapeutics Balance Sheet

 31 Dec 2015 (GBP)31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)
 31 Dec 2015 (GBP)31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)
fixed assets fixed assets0.020.59%0.020.04%0.010.03%0.010.02%m
intangibles intangibles0.5117.94%28.9855.33%29.9666.62%30.9671.36%m
fixed investments fixed investments--%--%--%--%m
current assets - other current assets - other--%--%--%--%m
stocks stocks--%0.420.80%0.130.28%0.110.25%m
debtors debtors1.6156.12%1.993.79%1.573.50%2.535.83%m
cash & securities cash & securities0.7325.35%20.9840.05%13.3029.57%9.7822.54%m
creditors - short creditors - short3.58125.00%3.997.61%3.768.37%2.956.80%m
creditors - long creditors - long17.93626.85%--%--%--%m
creditors - other creditors - other--%--%--%--%m
subordinated loans subordinated loans--%--%--%--%m
insurance funds insurance funds--%--%--%--%m
ord cap, reserves ord cap, reserves-18.64-651.85%48.4092.39%41.2191.63%40.4393.20%m
prefs, minorities prefs, minorities--%--%--%--%m
NAV Basic- - - - 
NAV Diluted- - - - 

Shield Therapeutics Cash Flow Statement

31 Dec 2015 (GBP)31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)
Operating CF-4.18-10.26-16.15-0.18m
Pre-Financing CF-4.32-13.25-19.56-3.52m
Retained CF0.2520.25-7.68-3.52m

Shield Therapeutics Brokers

Broker infomation is not available for this class of stock.
Your Recent History
Shield The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20191212 02:45:52